250 related articles for article (PubMed ID: 37819499)
1. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
[TBL] [Abstract][Full Text] [Related]
2. Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.
Drexel H; Leiherer A; Saely CH; Brandtner EM; Geiger K; Vonbank A; Fraunberger P; Muendlein A
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 30988077
[TBL] [Abstract][Full Text] [Related]
3. Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations.
Ordelheide AM; Böhm A; Kempe-Teufel D; Wagner R; Machicao F; Heni M; Stefan N; Fritsche A; Häring HU; Staiger H
PLoS One; 2017; 12(5):e0177148. PubMed ID: 28472182
[TBL] [Abstract][Full Text] [Related]
4. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Zimdahl H; Haupt A; Brendel M; Bour L; Machicao F; Salsali A; Broedl UC; Woerle HJ; Häring HU; Staiger H
Pharmacogenet Genomics; 2017 Apr; 27(4):135-142. PubMed ID: 28134748
[TBL] [Abstract][Full Text] [Related]
5. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
Tönjes A; Kovacs P
Pharmacogenomics; 2013 May; 14(7):825-33. PubMed ID: 23651029
[TBL] [Abstract][Full Text] [Related]
6. Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients.
Klen J; Goričar K; Dolžan V
J Med Biochem; 2020 Sep; 39(3):276-282. PubMed ID: 33269015
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
8. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of novel glucose-lowering drugs.
Rathmann W; Bongaerts B
Diabetologia; 2021 Jun; 64(6):1201-1212. PubMed ID: 33594477
[TBL] [Abstract][Full Text] [Related]
10. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
11. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations.
Klen J; Dolžan V
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575958
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
Kashiwagi A; Maegawa H
J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
[TBL] [Abstract][Full Text] [Related]
13. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
14. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B; Li S; Kang B; Zhou J
Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
18. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
[TBL] [Abstract][Full Text] [Related]
19. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
20. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
